MDT

89.34

+0.27%↑

VEEV

281.18

-0.98%↓

124.13

+2.21%↑

WBA

11.54

-0.09%↓

HQY

97.12

-2.5%↓

MDT

89.34

+0.27%↑

VEEV

281.18

-0.98%↓

124.13

+2.21%↑

WBA

11.54

-0.09%↓

HQY

97.12

-2.5%↓

MDT

89.34

+0.27%↑

VEEV

281.18

-0.98%↓

124.13

+2.21%↑

WBA

11.54

-0.09%↓

HQY

97.12

-2.5%↓

MDT

89.34

+0.27%↑

VEEV

281.18

-0.98%↓

124.13

+2.21%↑

WBA

11.54

-0.09%↓

HQY

97.12

-2.5%↓

MDT

89.34

+0.27%↑

VEEV

281.18

-0.98%↓

124.13

+2.21%↑

WBA

11.54

-0.09%↓

HQY

97.12

-2.5%↓

Home・Lista de Ações・Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc

Fechado

SetorSaúde

8.94 6.81

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

8.37

Máximo

9.08

Indicadores-chave
By Trading Economics
Rendimento	22M 23M
Vendas	2.6M 62M
P/E Médio do Setor	27.667 39.564
Margem de lucro	37.371
Funcionários	130
EBITDA	15M 22M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+14.42% upside

Dividendos
By Dow Jones
Próximos Ganhos	31 de jul. de 2025

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-119M 1B
Abertura anterior	2.13
Fecho anterior	8.94

Sentimento de Notícias

By Acuity

50%

168 / 376 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

8.1 / 8.21 Suporte e Resistência

Aurinia Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de jul. de 2025, 21:42 UTC

Aquisições, Fusões, Aquisições de Empresas

Justice Department Won't Seek Injunction for T-Mobile Acquisition of U.S. Cellular

10 de jul. de 2025, 17:06 UTC

Aquisições, Fusões, Aquisições de Empresas

Portugal Begins Process to Sell Stake in National Carrier -- Update

10 de jul. de 2025, 17:00 UTC

Grandes Movimentos do Mercado

K Wave Media Shares Drop After Convertible Note Agreement With Anson Funds

10 de jul. de 2025, 16:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Blackstone Makes $664 Million Counteroffer for Warehouse REIT Amid Bidding War -- 2nd Update

10 de jul. de 2025, 23:47 UTC

Conversa de Mercado

Gold Edges Higher Amid Lingering Global Trade Tensions -- Market Talk

10 de jul. de 2025, 23:40 UTC

Conversa de Mercado

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

10 de jul. de 2025, 22:36 UTC

Conversa de Mercado

Tourism Holdings' Profit Warning Less Concerning Than Others -- Market Talk

10 de jul. de 2025, 22:23 UTC

Conversa de Mercado

New Law Creates Winners and Losers Among Renewable-Energy Projects -- Market Talk

10 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Ganhos

Auto & Transport Roundup: Market Talk

10 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

10 de jul. de 2025, 20:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Toyota Tsusho America Completes Acquisition of Radius Recycling

10 de jul. de 2025, 19:56 UTC

Conversa de Mercado

Gold Rises on Inflation Concerns -- Market Talk

10 de jul. de 2025, 19:33 UTC

Conversa de Mercado

Oil Snaps Winning Streak As Oversupply Concerns Return -- Market Talk

10 de jul. de 2025, 19:21 UTC

Conversa de Mercado

U.S. Natural Gas Rebound on Benign Storage Build -- Market Talk

10 de jul. de 2025, 18:46 UTC

Conversa de Mercado

Mexican Industrial Production Seen as Mixed in May -- Market Talk

10 de jul. de 2025, 18:15 UTC

Conversa de Mercado

Brazil's Bullish Outlook Expected to Survive Trump Tariffs -- Market Talk

10 de jul. de 2025, 18:03 UTC

Conversa de Mercado

Ganhos

Travel Agency Investors Cautiously Optimistic After Delta Report -- Market Talk

10 de jul. de 2025, 17:57 UTC

Conversa de Mercado

US Labor Shortage Could Weigh on Business, Economic Growth -- Market Talk

10 de jul. de 2025, 17:34 UTC

Ganhos

Aquisições, Fusões, Aquisições de Empresas

Conagra Falls While Simply Good Foods Adapts. What's Eating Food Companies. -- Barrons.com

10 de jul. de 2025, 17:34 UTC

Conversa de Mercado

Canada Vows Fight Over Trump's Copper Tariffs -- Market Talk

10 de jul. de 2025, 17:20 UTC

Conversa de Mercado

Copper Climbs as Futures Wrangle With Trump Tariff -- Market Talk

10 de jul. de 2025, 17:20 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

10 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

10 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

10 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

10 de jul. de 2025, 16:02 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

10 de jul. de 2025, 16:02 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

10 de jul. de 2025, 16:02 UTC

Conversa de Mercado

Embraer Expected to Bear Brunt of U.S. Tariffs on Brazil -- Market Talk

10 de jul. de 2025, 16:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Investor AB: Advanced Instruments' Acquisition of Nova Biomedical Completed

10 de jul. de 2025, 15:41 UTC

Conversa de Mercado

U.S. Natural Gas Storage Surplus Holds Steady -- Market Talk

Comparação entre Pares

Variação de preço

Aurinia Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

14.42% parte superior

Previsão para 12 meses

Média 9.6 USD 14.42%

Máximo 11 USD

Mínimo 8 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Aurinia Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

Comprar

Manter

Vender

Com base em 5 analistas que deram avaliações de ações para Aurinia Pharmaceuticals Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

8.1 / 8.21Suporte e Resistência

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There is one bullish event.

Sentimento

By Acuity

168 / 376 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.